Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Communication | 12 | 2025 | 596 | 3.290 |
Why?
|
| Physicians | 4 | 2025 | 474 | 1.740 |
Why?
|
| Vaccination | 5 | 2025 | 377 | 1.350 |
Why?
|
| Patient Satisfaction | 3 | 2019 | 439 | 1.330 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 5 | 2021 | 703 | 1.200 |
Why?
|
| Qualitative Research | 5 | 2025 | 750 | 1.140 |
Why?
|
| Physician-Patient Relations | 4 | 2025 | 425 | 1.120 |
Why?
|
| Patient-Centered Care | 4 | 2019 | 256 | 1.110 |
Why?
|
| Hospitals | 4 | 2020 | 387 | 1.100 |
Why?
|
| Patients | 2 | 2020 | 115 | 1.050 |
Why?
|
| Decision Making | 3 | 2025 | 417 | 0.960 |
Why?
|
| Quality of Health Care | 3 | 2019 | 528 | 0.920 |
Why?
|
| Health Care Surveys | 3 | 2019 | 288 | 0.760 |
Why?
|
| Focus Groups | 1 | 2024 | 319 | 0.750 |
Why?
|
| Attitude of Health Personnel | 3 | 2025 | 624 | 0.730 |
Why?
|
| Influenza Vaccines | 1 | 2023 | 97 | 0.720 |
Why?
|
| Early Detection of Cancer | 1 | 2025 | 325 | 0.690 |
Why?
|
| Primary Health Care | 2 | 2024 | 721 | 0.690 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 460 | 0.670 |
Why?
|
| Male | 24 | 2025 | 31047 | 0.670 |
Why?
|
| Patient Participation | 2 | 2024 | 234 | 0.660 |
Why?
|
| Delivery of Health Care | 3 | 2019 | 431 | 0.650 |
Why?
|
| Adult | 13 | 2025 | 17358 | 0.640 |
Why?
|
| Humans | 37 | 2025 | 65140 | 0.640 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2025 | 496 | 0.640 |
Why?
|
| Vaccines | 1 | 2021 | 96 | 0.630 |
Why?
|
| Self-Management | 1 | 2021 | 71 | 0.620 |
Why?
|
| Aged | 18 | 2025 | 14965 | 0.610 |
Why?
|
| Noninvasive Ventilation | 2 | 2017 | 68 | 0.610 |
Why?
|
| Vaccination Coverage | 1 | 2019 | 9 | 0.610 |
Why?
|
| Middle Aged | 15 | 2025 | 18273 | 0.590 |
Why?
|
| Female | 23 | 2025 | 34018 | 0.590 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 407 | 0.590 |
Why?
|
| Mass Screening | 1 | 2025 | 698 | 0.590 |
Why?
|
| Patient Care | 1 | 2019 | 79 | 0.580 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 767 | 0.580 |
Why?
|
| Massachusetts | 8 | 2025 | 2145 | 0.580 |
Why?
|
| Patient Comfort | 1 | 2018 | 3 | 0.570 |
Why?
|
| Continuity of Patient Care | 2 | 2017 | 174 | 0.570 |
Why?
|
| Attitude to Health | 1 | 2020 | 296 | 0.550 |
Why?
|
| Lung Neoplasms | 1 | 2025 | 702 | 0.540 |
Why?
|
| Medical Errors | 2 | 2017 | 200 | 0.520 |
Why?
|
| Comprehension | 1 | 2018 | 138 | 0.510 |
Why?
|
| Professional-Family Relations | 1 | 2016 | 91 | 0.450 |
Why?
|
| Hospital Mortality | 3 | 2017 | 875 | 0.430 |
Why?
|
| Length of Stay | 2 | 2017 | 828 | 0.420 |
Why?
|
| Trust | 2 | 2024 | 79 | 0.400 |
Why?
|
| Critical Illness | 1 | 2016 | 330 | 0.370 |
Why?
|
| Quality Improvement | 3 | 2025 | 464 | 0.360 |
Why?
|
| Inpatients | 1 | 2015 | 319 | 0.360 |
Why?
|
| Cross-Sectional Studies | 5 | 2024 | 2701 | 0.350 |
Why?
|
| Young Adult | 4 | 2025 | 4809 | 0.330 |
Why?
|
| Interviews as Topic | 3 | 2017 | 531 | 0.320 |
Why?
|
| United States | 9 | 2024 | 8093 | 0.320 |
Why?
|
| Heart Failure | 3 | 2015 | 957 | 0.320 |
Why?
|
| Patient Safety | 3 | 2018 | 259 | 0.320 |
Why?
|
| Surveys and Questionnaires | 4 | 2025 | 2757 | 0.290 |
Why?
|
| Activities of Daily Living | 2 | 2021 | 293 | 0.290 |
Why?
|
| Pandemics | 2 | 2025 | 674 | 0.270 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2020 | 159 | 0.260 |
Why?
|
| Neoplasms | 1 | 2017 | 1368 | 0.250 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2006 | 14 | 0.250 |
Why?
|
| Epoprostenol | 1 | 2006 | 15 | 0.250 |
Why?
|
| Acute Disease | 3 | 2017 | 663 | 0.240 |
Why?
|
| Hypertension, Pulmonary | 1 | 2006 | 99 | 0.230 |
Why?
|
| Blood Vessels | 1 | 2006 | 63 | 0.230 |
Why?
|
| Retrospective Studies | 6 | 2020 | 6872 | 0.220 |
Why?
|
| Antihypertensive Agents | 1 | 2006 | 179 | 0.220 |
Why?
|
| Longitudinal Studies | 3 | 2023 | 1282 | 0.220 |
Why?
|
| Hospitalization | 4 | 2021 | 1392 | 0.210 |
Why?
|
| Stem Cells | 1 | 2006 | 276 | 0.200 |
Why?
|
| Faculty, Medical | 1 | 2025 | 200 | 0.200 |
Why?
|
| Physicians, Primary Care | 1 | 2024 | 78 | 0.200 |
Why?
|
| Cooperative Behavior | 2 | 2025 | 229 | 0.180 |
Why?
|
| Knowledge | 1 | 2022 | 32 | 0.180 |
Why?
|
| Intention | 1 | 2022 | 73 | 0.180 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 5614 | 0.180 |
Why?
|
| Ecosystem | 1 | 2022 | 58 | 0.180 |
Why?
|
| Disease Progression | 4 | 2019 | 1220 | 0.170 |
Why?
|
| Patient Discharge | 2 | 2017 | 519 | 0.170 |
Why?
|
| Intensive Care Units | 2 | 2016 | 420 | 0.170 |
Why?
|
| Lung | 1 | 2006 | 966 | 0.160 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2019 | 35 | 0.150 |
Why?
|
| Reminder Systems | 1 | 2019 | 75 | 0.140 |
Why?
|
| District of Columbia | 1 | 2018 | 9 | 0.140 |
Why?
|
| Maryland | 1 | 2018 | 36 | 0.140 |
Why?
|
| Motivation | 1 | 2021 | 296 | 0.140 |
Why?
|
| Homes for the Aged | 1 | 2020 | 166 | 0.140 |
Why?
|
| Uncertainty | 1 | 2018 | 39 | 0.140 |
Why?
|
| Health Education | 1 | 2019 | 189 | 0.140 |
Why?
|
| Culture | 1 | 2018 | 82 | 0.140 |
Why?
|
| Calcitonin | 1 | 2017 | 17 | 0.130 |
Why?
|
| Patient Preference | 1 | 2018 | 86 | 0.130 |
Why?
|
| Inventories, Hospital | 1 | 2017 | 3 | 0.130 |
Why?
|
| Nursing Homes | 2 | 2021 | 686 | 0.130 |
Why?
|
| Hospitals, Low-Volume | 1 | 2017 | 20 | 0.120 |
Why?
|
| Medicare | 1 | 2021 | 625 | 0.120 |
Why?
|
| Hospitals, High-Volume | 1 | 2017 | 36 | 0.120 |
Why?
|
| Electronic Health Records | 1 | 2019 | 393 | 0.120 |
Why?
|
| Survival Rate | 2 | 2015 | 844 | 0.120 |
Why?
|
| Homosexuality, Male | 1 | 2015 | 29 | 0.110 |
Why?
|
| Registries | 1 | 2019 | 924 | 0.110 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2015 | 51 | 0.110 |
Why?
|
| Adolescent | 2 | 2024 | 6297 | 0.110 |
Why?
|
| Mother-Child Relations | 1 | 2015 | 45 | 0.110 |
Why?
|
| Patient Care Team | 1 | 2017 | 335 | 0.110 |
Why?
|
| Multiple Myeloma | 1 | 2019 | 369 | 0.110 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 140 | 0.100 |
Why?
|
| Comorbidity | 2 | 2015 | 1119 | 0.100 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2015 | 152 | 0.100 |
Why?
|
| Algorithms | 1 | 2019 | 1050 | 0.100 |
Why?
|
| Databases, Factual | 1 | 2017 | 883 | 0.100 |
Why?
|
| Outpatients | 1 | 2015 | 143 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2017 | 5792 | 0.100 |
Why?
|
| Stroke Volume | 1 | 2014 | 342 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 801 | 0.090 |
Why?
|
| Mortality | 1 | 2012 | 161 | 0.080 |
Why?
|
| Data Collection | 1 | 2012 | 382 | 0.080 |
Why?
|
| HIV Infections | 1 | 2015 | 955 | 0.070 |
Why?
|
| Telemedicine | 1 | 2012 | 362 | 0.060 |
Why?
|
| Vascular Resistance | 1 | 2006 | 47 | 0.060 |
Why?
|
| Infusions, Intravenous | 1 | 2006 | 175 | 0.060 |
Why?
|
| Pulmonary Veins | 1 | 2006 | 35 | 0.060 |
Why?
|
| Myocardial Infarction | 1 | 2012 | 919 | 0.060 |
Why?
|
| Pulmonary Artery | 1 | 2006 | 96 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 856 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2006 | 526 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2024 | 261 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2021 | 3308 | 0.050 |
Why?
|
| Mobile Applications | 1 | 2024 | 140 | 0.050 |
Why?
|
| Risk Factors | 3 | 2020 | 5429 | 0.040 |
Why?
|
| Universities | 1 | 2022 | 168 | 0.040 |
Why?
|
| Logistic Models | 2 | 2015 | 1269 | 0.040 |
Why?
|
| Polypharmacy | 1 | 2020 | 67 | 0.040 |
Why?
|
| Long-Term Care | 1 | 2020 | 179 | 0.040 |
Why?
|
| Prognosis | 2 | 2014 | 1784 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1141 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 405 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1113 | 0.030 |
Why?
|
| Unsafe Sex | 1 | 2015 | 27 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 930 | 0.030 |
Why?
|
| Risk-Taking | 1 | 2015 | 159 | 0.030 |
Why?
|
| Cause of Death | 1 | 2014 | 221 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2017 | 451 | 0.020 |
Why?
|
| Renal Insufficiency | 1 | 2012 | 67 | 0.020 |
Why?
|
| Biomarkers | 1 | 2017 | 1480 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2012 | 576 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 2102 | 0.020 |
Why?
|
| Sex Factors | 1 | 2012 | 992 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 2483 | 0.020 |
Why?
|
| Age Factors | 1 | 2012 | 1586 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 734 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 1698 | 0.020 |
Why?
|
| Animals | 1 | 2006 | 21345 | 0.020 |
Why?
|
| Time Factors | 1 | 2014 | 3762 | 0.020 |
Why?
|